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Abstract
Introduction: Our purpose was to compare the safety and efficacy of food and drug administration (FDA)
recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension.
Methods: Multicenter randomized clinical trial. Eligible patients had 2 systolic blood pressure (SBP) measures ≥180
mmHg and no contraindications to nicardipine or labetalol. Before randomization, the physician specified a target
SBP ± 20 mmHg (the target range: TR). The primary endpoint was the percent of subjects meeting TR during the
initial 30 minutes of treatment.
Results: Of 226 randomized patients, 110 received nicardipine and 116 labetalol. End organ damage preceded
treatment in 143 (63.3%); 71 nicardipine and 72 labetalol patients. Median initial SBP was 212.5 (IQR 197, 230) and
212 mmHg (IQR 200,225) for nicardipine and labetalol patients (P = 0.68), respectively. Within 30 minutes,
nicardipine patients more often reached TR than labetalol (91.7 vs. 82.5%, P = 0.039). Of 6 BP measures (taken every
5 minutes) during the study period, nicardipine patients had higher rates of five and six instances within TR than
labetalol (47.3% vs. 32.8%, P = 0.026). Rescue medication need did not differ between nicardipine and labetalol
(15.5 vs. 22.4%, P = 0.183). Labetalol patients had slower heart rates at all time points (P < 0.01). Multivariable
modeling showed nicardipine patients were more likely in TR than labetalol patients at 30 minutes (OR 2.73, P =
0.028; C stat for model = 0.72)
Conclusions: Patients treated with nicardipine are more likely to reach the physician-specified SBP target range
within 30 minutes than those treated with labetalol.
Trial registration: ClinicalTrials.gov: NCT00765648
Introduction
Hypertensive emergencies require immediate, controlled
blood pressure (BP) reduction and intensive care moni-
toring to avoid or limit end-organ damage [1]. Without
proper treatment, the one year mortality of hypertensive
e m e r g e n c i e si sa sh i g ha s7 9 % .W i t ha p p r o p r i a t et r e a t -
ment, this decreases to 25% [2]. Although BP reduction
is essential, antihypertensive therapy must be tailored to
each patient’s specific needs and clinicians must avoid
the potential for harm caused by excessive BP lowering
[1,3]. Too great or too fast of a reduction in BP may
lead to end-organ hypoperfusion, potentially resulting in
ischemia and infarction [1]. Unfortunately, a lack of
acute clinical trials has left clinicians with little evi-
dence-based guidance as to the optimal agent for BP
control. Two agents commonly used for the manage-
ment of acute hypertensive crises are intravenous (IV)
nicardipine and labetalol. Nicardipine is a titratable IV
dihydropyridine calcium ion influx inhibitor (i.e., cal-
cium channel blocker) with dosing that is independent
o fb o d yw e i g h t .I ti sg i v e na sa ni n f u s i o na n di t so n s e t
of action is 5 to 15 minutes, with a clinical offset of
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blood pressure (SBP) or diastolic blood pressure (DBP)
after stopping infusion) within 30 minutes (range of 5 to
120 minutes) [4]. After an IV infusion, nicardipine
plasma concentrations decline tri-exponentially, with a
rapid early distribution phase (a-half-life of 2.7 min-
utes), an intermediate phase (b-half-life of 44.8 minutes),
and a slow terminal phase (g-half-life of 14.4 hours) that
can only be detected after long-term infusions. Nicardi-
pine is rapidly and extensively metabolized by the liver,
with excretion roughly equally in the feces and urine.
Although nicardipine is as effective as sodium nitroprus-
side at lowering SBP, unlike nitroprusside, nicardipine
reduces both cardiac and cerebral ischemia [4]. Nicardi-
pine has high arterial vascular selectivity, with strong
coronary and cerebral vasodilator effect that results in
increased coronary and cerebral blood flow [5].
Labetalol hydrochloride is an IV antihypertensive with
both selective alpha- and non-selective beta-adrenergic
receptor blocking actions. Labetalol is recommended to
be given as a bolus injection, with dose escalations every
10 minutes until the goal BP is reached. Metabolized by
the liver to form an inactive glucuronide conjugate, it
has an onset of action within two to five minutes,
reaches peak effects at 5 to 15 minutes, has an elimina-
tion half life of 5.5 hours, and duration of action of up
to four hours.
In a recent retrospective analysis of neurologic critical
care cerebrovascular accident (CVA) patients, nicardi-
pine required fewer dosage adjustments than labetalol,
and provided decreased need for additional use of anti-
h y p e r t e n s i v e sa g e n t s[ 6 ] .I ti su n k n o w nw h e t h e rt h e s e
findings would translate to other patient populations in
other care settings. Thus far, no emergency department
(ED) comparative effectiveness trial of these agents has
been conducted. Our purpose was to perform a phase
four, randomized, comparative effectiveness trial to
determine the efficacy and safety of a premixed nicardi-
pine infusion versus IV bolus labetalol for management
of hypertension in the ED setting.
Materials and methods
This investigation was performed at 13 US academic
EDs, each with institutional review board approval.
Registered at ClinicalTrials.gov, with identifier is
NCT00765648, this study was conducted in accordance
with Good Clinical Practices and in compliance with all
applicable subject privacy requirements.
After meeting all eligibility criteria, and obtaining con-
sent, patients were prospectively enrolled into the study.
Before randomization, which was stratified by center,
the treating physician was required to define a target
SBP. The target SBP was determined at the discretion of
the physician, based on their impression of necessity for
a given clinical scenario. A target range was defined as
the target SBP ± 20 mmHg. To meet the primary end-
point, patients were required to be within the target
SBP range by 30 minutes; transient time but not within
the target range at 30 minutes was not considered to be
within the target range. Subjects were then randomized
in a 1:1 ratio to receive either a nicardipine infusion as
a premixed formulation or bolus IV labetalol. The active
treatment phase was 30 minutes. Any treatment after 30
minutes was at physician discretion. The study data col-
lection period was for the first six hours following
enrollment.
To be eligible for CLUE, patients had to be older
than18 years of age, with a SBP of 180 mmHg or more
on two consecutive readings (10 minutes apart), and
able to provide signed informed consent, including
authorization to use protected health information.
Patients were ineligible if they had specific contraindica-
tions to receiving either a beta blocker or a calcium
channel blocker, or if they were believed to suffer from
a condition associated with an evidence-based guideline
indication precluding randomization to another agent (e.
g., in the setting of an acute myocardial infarction, beta-
blockade is indicated and patients were excluded as they
should not be randomized to a calcium channel
blocker). Patients were also excluded if they met any of
the following criteria: use of any investigational drug
within 30 days, pregnant or breast-feeding, contraindica-
tions or allergy to beta-blockers or calcium channel
blockers, advanced aortic stenosis, bronchial asthma,
overt cardiac failure, greater than first-degree heart
block, cardiogenic shock, severe bradycardia, obstructive
airway disease, decompensated heart failure, a known
left ventricular ejection fraction of less than 35%, history
of CVA within 30 days, known impaired hepatic func-
tion, suspected myocardial infarction, suspected aortic
dissection, suspected cocaine use as the cause of ED
presentation, or if they were concurrently receiving any
IV antihypertensive medication.
Although medication dosing was per the physician’s
discretion, the US Food and Drug Administration (FDA)
recommended dosing schedules were provided, and
their use encouraged. We chose the FDA recommenda-
tions because this study was performed in the US,
where regulatory agencies determine how medications
are presented to physicians, and regulatory guidance
represents the most common way medications are used.
Nicardipine is recommended to be administered at 5
mg/hour and increased every five minutes by 2.5 mg/
hour, until the target SBP range is reached or a maxi-
mum of 15 mg/hour is achieved. Once in the target SBP
range, it is recommended that the infusion rate be
decreased to 3 mg/hour. Labetalol dosing recommenda-
tions are for an initial IV bolus of 20 mg over two
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injections every 10 minutes until the target SBP range is
reached, or a maximum of 300 mg has been given.
Randomized patients were required to receive the first
dose of study drug as soon as possible, ideally within 30
minutes of enrollment. Blood pressures were monitored
via automatic cuff every five minutes during the 30 min-
ute active phase. During the first 30 minutes after study
drug initiation, the use of any additional antihyperten-
sive was discouraged. Vital signs and potential adverse
event occurrence was monitored for six hours or to ED
discharge, whichever came first, after the initiation of
study drug. Patient disposition (e.g., clinical decision
unit, hospitalization, etc), time of transition to oral med-
ication, and mortality status were determined at 48
hours after enrollment.
Clinical data were collected as soon as possible after
enrollment, but were not required to be completed prior
to study drug initiation. This included past medical his-
tory, hemoglobin, hematocrit, blood urea nitrogen
(BUN), creatinine, sodium, potassium, glucose, dipstick
urinalysis (and microscopic analysis if abnormal), B-type
natriuretic peptide (BNP) level, and troponin. Medica-
tions taken one week prior to screening, and the assess-
ment of baseline signs and symptoms were documented.
At discharge, adverse events were recorded. Length of
ICU or hospital stay, date and cause of any deaths (with
autopsy data if available), were also recorded.
The presence of end-organ damage was defined as
having any one of the following symptoms suggestive of
a hypertensive emergency at presentation: chest pain,
shortness of breath, epigastric discomfort, syncope, diz-
ziness, blurred vision, diplopia, diminished level of con-
sciousness, confusion, hematuria, or the development
acute ischemic changes on a 12 lead electrocardiogram
(ECG).
Statistical analysis
The proportion of patients in each arm achieving the
target BP within 30 minutes was compared with chi-
square analysis. We predicted 55% of labetalol patients
would achieve target BP range within 30 minutes. Using
a two-sided alpha of 0.05, and assuming a 10% drop out
rate, 113 patients in each arm provided 85% power to
detect an absolute 20% effect size (75% achieving target
range) in the nicardipine group.
Randomization was stratified by site. At each site
patients were randomized in a 1:1 ratio. Allocation to
nicardipine or labetalol was balanced in blocks of four
for each of the 13 sites. Sealed envelopes were created
by C5 (the coordinating research organization), and pro-
vided to the sites. Each had a label indicating the proto-
col name, site number, and patient study ID number.
Randomization slips in the envelope contained the same
information as the labels, as well as the randomized
treatment. Sequence was concealed until interventions
were assigned. Patients were enrolled by each site’s
research coordinator who was blinded to the randomiza-
tion process.
Demographic tables include all randomized patients.
Primary efficacy (all randomized patients) and safety (all
patients receiving at least one dose of study medication)
endpoints include only patients who completed the first
30 minutes of the study. For outcomes, dichotomous
variables were compared by Chi-square or Fisher’s Exact
test where appropriate, and continuous variables by Stu-
dent’s T-test or appropriate nonparametric test. Missing
values were not imputed and only observed values were
used for analyses. A multivariable logistic model to
assess the factors for “met target SBP within 30 min-
utes”, after controlling for site differences, was devel-
oped (Table 1). All baseline variables with no more than
10% missing data points were considered for inclusion
into an adjusted model. A stepwise elimination proce-
dure was used to determine the final model. A P value
less than 0.05 was considered as a significant risk factor
and included in the final model. All statistical analyses
were performed using SAS version 9.1 (SAS Institute,
Cary, NC, USA).
Results
We enrolled 226 patients from 13 centers, from 16
December, 2008 until 19 January, 2010. Overall, 53%
were female, and 76% were black, with a mean age of
52.6 ± 14.6 years. Randomization resulted in 110
patients receiving nicardipine and 116 labetalol, with
enrollment as per Figure 1. Time from ED admission
until study drug administration was similar for the
nicardipine (median 2.0, interquartile range (IQR) 1.5,
2.8) and labetalol groups (median 1.9, IQR 1.3, 2.7
hours; P = 0.338).
Demographic, historical clinical, and laboratory para-
meters are presented in Table 2. Of these the nicardi-
pine cohort was more likely to be diabetic (P =0 . 0 3 )o r
have hyperlipidemia (P = 0.02), and the labetalol cohort
was more likely to have a social history of past and/or
current smoking (P = 0.02; Table 2).
Table 1 Final multivariable logistic regression model† for
“met target systolic blood pressure within first 30
minutes”.
Factors Odds ratio 95% confidence interval
Nicardipine vs. labetalol 2.73 1.113-6.698
Female 3.311 1.36-8.064
No history of stroke 5.38 1.565-18.468
† Site is adjusted in the model.
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nicardipine and labetalol populations in regards to past
medical history. More than 90% had a history of hyper-
tension, and roughly one third had a prior hypertensive
emergency hospitalization. Although there was little car-
diovascular disease at presentation due to our exclusion
criteria, the overall rates and interventions for these
pathologies did not appear to differ between cohorts.
Consistent with this similarity, there were very few dif-
ferences in medications used before study enrollment.
Finally, self-reported stimulant (cocaine and metham-
phetamine) use was similar between the two treatment
groups.
Signs and symptoms of end-organ damage preceding
treatment occurred in 143 (63.3%), and at similar
rates between cohorts (n = 71, 64.5% for nicardipine,
and n = 72, 62.1% for labetalol). The presence of end-
organ damage was associated with a history of asthma,
diabetes, myocardial infarction, renal failure, hepatitis,
race, and a prior history of hypertension. Similar to the
overall group, more end-organ damage patients receiv-
ing nicardipine were within target range within 30 min-
utes, than those treated with labetalol, 91.4% vs 76.1%
(P = 0.014), respectively.
Overall, in the intent to treat cohort the initial median
SBP (IQR) was 211 (198, 226) mmHg; 212.5 (IQR 197,
230), and 212 mmHg (IQR 200, 225) in the nicardipine
and labetalol groups (P = 0.68), respectively (Table 3).
Initial target SBP were similar and are presented in
Table 3 Patients treated with either nicardipine or
labetalol both experienced relevant BP decreases during
treatment; however, by 15 minutes the nicardipine and
labetalol response curves had significantly separated
(Figure 2).
Within 30 minutes, nicardipine patients more often
reached target range than did those treated with labeta-
lol (91.7 vs. 82.5%, 95% confidence interval (CI) -18.0 to
-0.6). Of the six BP measures obtained during the study
period (BP measured every five minutes) nicardipine
patients more often had five and six measures within
target range than did the labetalol cohort (47.3% vs.
32.8%, 95% CI of the difference -27.2 to -1.9). To evalu-
a t ev a r i a b i l i t yo fB Pc o n t r o l ,t h em e a na r e au n d e rt h e
curve (AUC) for time and depth of measures outside
the SBP target range was calculated. There was no
difference between nicardipine and labetalol patients
with respect to median AUC (96.4 vs. 104.9 mmHg/min,
P = 0.558). At study completion, median (IQR) SBP for
the entire cohort was 165.0 (154.5, 182.0). It was 163.0
(154.0, 177.0), and 168.0 (156.0, 184.0) mmHg (95%
CI of the difference between groups -13.3 to -2.0) for
nicardipine and labetalol, respectively.
Important to the understanding of BP response is
determining if nicardipine and labetalol dosing was
Randomized 
(n=226  )
Randomized to receive Nicardipine 
(n=110  )
Received study drug as assigned 
(n=109 )
Randomized to receive Labetalol 
(n=116  )
Received study drug as assigned 
(n=116  )
Patient withdrew consent and lost to 
follow-up (n=1)
Patient withdrew consent and lost to 
follow-up (n=2)
Analysed 
• included in safety analysis (n=110)
• included in primary endpoint analysis 
(n=109)
Analysed  
• included in safety analysis  (n=116)
• included in primary endpoint 
analysis (n=114)
Figure 1 Patient entry into CLUE trial.
Table 2 Comparison of the characteristics of patients
receiving either nicardipine or labetalol
Characteristic n (%), unless otherwise
indicated
Nicardipine
(n = 110)
Labetalol
(n = 116)
Mean age, years ± SD 53.3 ± 15.3 51.9 ± 13.9
Female 60 (54.6) 59 (50.9)
White 28 (25.5) 24 (20.9)
African American 82 (74.6) 90 (78.3)
Smoking history 54 (49.1) 78 (67.2)
Current smoker 30 (27.3) 49 (42.2)
Stimulant use history (cocaine or
amphetamines)
17 (15.5) 23 (19.8)
Median basal metabolic index (IQR) 29.3 (24.5,
34.3)
29.4 (25.1,
34.0)
Median heart rate, bpm (IQR) 85 (76, 98) 85 (73, 97)
Chest pain 33(30.0) 26 (22.4)
Diminished consciousness 1 (0.9) 5 (4.3)
Headache 48 (43.6) 58 (50.0)
Shortness of breath 34 (30.9) 27 (23.3)
Past medical history
Hypertension 105 (96.3) 109 (94.0)
Hypertension crisis hospitalization 40 (38.8) 39 (36.4)
Hyperlipidemia 46 (43.4) 31 (27.9)
Diabetes 38 (34.6) 25 (21.7)
Coronary artery disease 17 (15.7) 15 (13.0)
Dialysis 16 (14.6) 12 (10.5)
Stroke 10 (9.2) 7 (6.2)
Heart failure 8 (7.3) 12 (10.6)
Myocardial infarction 7 (6.5) 7 (6.03)
Baseline laboratory/ECG
Median creatinine, mg/dL (IQR) 1.2 (0.9, 3.0) 1.1 (0.9, 1.8)
Median BNP, pg/dL (IQR) 365.5 (117,
1981)
183.5 (125,
1825)
Median troponin I (ng/mL) 0.0 (0.0, 0.2) 0.0 (0.0, 0.1)
Abnormal electrocardiogram 25 (27.2) 28 (28.9)
BNP, B-type natriuretic peptide; IQR, interquartile range; SD, standard deviation.
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deviation) number of titrations for nicardipine were 2.2
± 1, and the mean number of doses of labetalol were 1.3
±0 . 9 7( P < 0.001). The median (IQR) dose of nicardi-
pine was 3.1 (2.3, 4.4) mg, compared with 40 (30, 80)
mg for labetalol. The dosing ranges were 1 to 6.7 mg
for nicardipine infusions, and 10 to 220 mg for bolus
labetalol. Further, there were no significant differences
between enrollment centers in regards to protocol
deviations, time to delivery of trial drug, or duration of
participation in the trial.
If patients did not attain target range SBP within the
30 minute study period, rescue medications could be
given at the physician’s discretion. Overall, the number
of patients receiving rescue medications was not statisti-
cally different between nicardipine and labetalol groups,
respectively (17 (15.5%) vs. 26 (22.4%), 95% CI of the
difference -3.1 to 17.5). If nicardipine failed, the first
rescue antihypertensive was most commonly labetalol
(used in 11 of 17) and was not particularly effective as
47.1% required at least one more rescue medication (in
addition to labetalol). If labetalol failed, the most
common rescue medication was nicardipine (used in 9
of 26), and only 7.7% required additional rescue
medication.
A d v e r s ee v e n t sa t t r i b u t e dt os t u d yd r u gw e r er a r e ,
occurring in only one nicardipine patient who developed
elevated cardiac markers after admission and no labeta-
lol patients. Labetalol patients had slower heart rates at
all time points after treatment (P < 0.01), although none
had a heart rate below 70 (Figure 3). Only three patients
did not complete the study (two labetalol and one nicar-
dipine), due to the withdrawal of consent.
Lowering BP below target range occurred in 14
(12.7%) nicardipine, and 13 (11.2%) of the labetalol-trea-
ted patients (95% CI of the difference -10.0 to 7.1).
The median (IQR) overshoot was 9.5 (3, 12.5) and 7.0
(3, 15.5) mmHg for nicardipine and labetalol cohorts,
respectively (95% CI of the difference -14.3 to 7.4). The
minimum and maximum overshoot of the target range
were 1 and 24 mmHg for nicardipine, and 1 and 69
mmHg for labetalol.
Hours from hospital admission until ED disposition
was similar between nicardipine (median 4.6, IQR 3.5,
6.6) and labetalol (median 4.6, IQR 3.1, 7.6), groups
(P = 0.762) and at discharge from the ED or hospital,
there were no differences in outpatient prescription
rates, with two exceptions. As expected in a cohort with
more hyperlipidemia, nicardipine patients were more
likely to receive an anti-lipid agent at discharge vs. the
labetalol cohort, 23.6% vs. 11.2% (95% CI of the differ-
ence -22.2 to -2.6). Nicardipine patients were also more
likely to be discharged on a calcium channel blocker
Table 3 Initial blood pressure and target ranges at enrollment
Parameter Descriptor Overall n = 226 Nicardipine n = 110 Labetalol n = 116 P Value
Initial SBP (mmHg) MEDIAN 211 212 210 0.682
NP
(Q1, Q3) (198, 226) (197, 230) (200, 225)
95% CI (210.6, 216.3) (209.8, 218.6) (209.0, 216.3)
MIN, MAX 163, 275 163, 275 180, 269
Initial DBP (mmHg) MEDIAN 116 112 118 0.272
NP
(Q1, Q3) (105, 126) (104, 125) (105, 127)
95% CI (114.4, 119.1) (112.3, 119.1) (114.5, 121.0)
(MIN, MAX) (84, 195) (84, 195) (86, 176)
Initial SBP target (mmHg) MEDIAN 165 169 165 0.071
NP
(Q1, Q3) (160, 175) (160, 180) (160, 170)
95% CI (164.2, 168) (165.4, 170.8) (161.5, 166.8)
(MIN, MAX) (105, 200) (132.5, 200) (105, 190)
CI, confidence interval; DBP, diastolic blood pressure; np, non-parametric test; SBP, systolic blood pressure.
Figure 2 SBP changes over time in patients randomized to
receive either nicardipine or labetalol. Mean percent change and
95% confidence interval (CI), evaluated by Student’s T test, relative
to presenting blood pressure, during the initial 30 minutes, with the
median upper level of target range and median target range
indicated by horizontal dotted lines, in patients randomized to
receive either nicardipine or labetalol. SBP, systolic blood pressure.
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25.9%; 95% CI of the difference -24.4 to -0.24).
Multivariable modeling adjusting for all significant
baseline variables (a total of three; drug type (P =
0.028), prior stroke (P = 0.008) and female gender (P =
0.008)), with enrollment site also forced into the model,
showed nicardipine patients were more likely to be in
target range by 30 minutes than patients receiving labe-
talol (odds ratio (OR) 2.73, 95% CI 1.1 to 6.7, C statistic
= 0.72, Hosmer and Lemeshow goodness of fit test P =
0.88 showing no significant lack of fit; Table 1). Finally,
to determine if chronic beta blocker or calcium channel
blocker use altered treatment response, we specifically
evaluated if a treatment effect occurred, based on
chronic medication usage, and found no interactions.
Discussion
Affecting nearly 500,000 patients in the US annually and
contributing to about 3% of all ED visits, [2,7,8], uncon-
trolled hypertension can be a serious and life-threaten-
ing presentation. For those with acute end-organ
dysfunction, immediate initiation of BP control is
needed and, even with aggressive management, in-hospi-
tal mortality in patients presenting with acute severe
hypertension exceeds 8% [9]. Achieving adequate BP
control can be challenging, as each patient requires anti-
hypertensive pharmacotherapy tailored to their specific
presentation. Although candidate drugs are available for
use in the acute setting, few studies have directly com-
pared antihypertensive agents in the ED.
We conducted the first randomized comparative effec-
tiveness trial directly evaluating the use of nicardipine
and labetalol in the ED management of acute hyperten-
sion. In this we demonstrated that patients receiving
nicardipine are more likely to have their BP controlled,
defined as within the physician’s prospectively defined
target range, than patients treated with labetalol (OR
2.73, P = 0.0283). Furthermore, the separation of BP
response curves between patients treated with either
nicardipine or labetalol reached statistical significance
within 15 minutes of implementation. We found only 1
in 10 nicardipine-treated patients failed to be in the tar-
get range by 30 minutes, compared with twice as many
if treated with labetalol. In clinically critical conditions
where rapid BP reduction would be considered optimal
(e.g., intracranial hemorrhage), nicardipine may be the
preferred first-line intervention.
Not unexpectedly, patients receiving labetalol had
greater heart rate reduction than did the nicardipine
group. Although controlled relative bradycardia is not
necessarily harmful, the potential for excessive heart
rate reduction may be considered, especially in light of
the patient’s pre-hospital medication use (e.g., already
on beta-blockade), their heart rate at presentation, and
if pre-existing cardiac conduction abnormalities are pre-
sent. Other contraindications to beta-blockade exist, and
include known chronic obstructive pulmonary disease,
acute heart failure, and cocaine overdose, where the
unopposed alpha effects may lead to hemodynamic
instability [1]. Labetalol has some advantages over selec-
tive beta blockers as it also possesses alpha-blocking
activity and may be appropriate in certain clinical
situations.
Conversely, although not evaluated in this analysis,
several conditions exist for which calcium channel
blockers are not recommended as first-line agents. This
is not necessarily because of a direct contraindication,
but rather that other agents have clinical or theoretical
advantages. This includes myocardial infarction, where
oral beta blockers confer a mortality reduction benefit,
and in the setting of aortic dissection where the negative
inotropic effect of beta blockers is desirable to decrease
shear forces in the false lumen of the dissection. In fact,
labetalol has been specifically recommended for use in
patients with aortic dissection because it has both alpha
and beta blockade effects.
Overall, iatrogenic complications were rare in both
treatment cohorts. Overshoot of BP below the specified
range occurred in less than 15% with either nicardipine
or labetalol. This may have been a function of the rela-
tively short duration of therapy of this study, and a
longer period may demonstrate different outcomes. The
potential for significant overshoot represents a serious
limitation in the use of any IV antihypertensive agent.
Excessive overshoot, resulting in iatrogenic hypotension,
may contribute to increased morbidity risk (e.g.,
hypoperfusion in watershed regions of the brain, result-
ing in acute CVA). Agents with this potential thus
require close hemodynamic monitoring, which may
impart an undue burden on ED nursing staff. Moreover,
Figure 3 Heart rate changes over time in patients randomized
to receive either nicardipine or labetalol. CI, confidence interval;
HR, heart rate.
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consequences, such as requiring ICU admission rather
than a step-down unit.
Our study is not without limitations. First, it was
unblinded and how this may have impacted outcomes is
unclear. Additionally, although most (63%) CLUE
patients had symptoms consistent with a hypertensive
emergency, some had elevated BP without evidence of
end-organ damage. In this later group it could be
argued acute BP control could have been deferred or
managed with oral agents. However, our primary objec-
tive was to determine which agent was most effective at
BP control for use in the ED patient population. This
strictly numerical outcome requires initially hypertensive
patients, but not necessarily those with end-organ injury,
and makes feasible a study with much smaller numbers
than would be required to power for clinical outcomes.
Also, the use of this model provides valuable data to
determine the most effective BP management agent
while deferring the ethical conflict of treating critical
patients with a potentially inferior agent.
Secondly, the separation of effect curves between
nicardipine and labetalol occur after 15 minutes. This
time period encompasses the period of re-dosing for
labetalol, and re-dosing was at the discretion of the
treating physician. Although this analysis was not
designed to determine why physicians dosed agents in
their chosen manner, the fact that physicians ordered
fewer doses of labetalol than titrations of nicardipine
may have impacted our results. Fewer labetalol titrations
m a yb et h er e s u l to ft h ed i f f i c u l t yi np e r f o r m i n gf r e -
quent bolus therapy in a busy ED, or the fear of iatro-
genic hypotension and bradycardia with too frequent
bolus therapy. Therefore the lack of rapid BP decline in
the labetalol cohort may be a result of insufficient dos-
ing by a physician hesitant to aggressively administer
successively increasing boluses of labetalol as is recom-
mended by the FDA.
Although the six-hour observation period of our study
can be criticized, this must be considered in view or our
primary endpoint which was to determine which agent
was most effective when rapid BP control was required.
As an IV agent that requires more than six hours to
control BP would have little use in the emergent sce-
nario, we limited the time of evaluation to a period we
felt was clinically relevant for rapid BP reduction.
Finally, the 30 minute definition of BP control may be
questioned. However, we felt that agents requiring
longer than this to control BP would be of lesser value
in clinical settings where rapid BP control may be
required to improve clinical outcomes. Furthermore,
since the BP goals were determined by the treating ED
physicians who were aware of the dosing parameters of
both study drugs and the study timelines, we feel that
our 30 minute goal to blood pressure control was a rea-
sonable time limit.
We did not complete a cost analysis of the two agents.
Although cost is also considered when an anti-hyperten-
sive agent is selected, such an analysis was beyond the
scope of this initial investigation.
Conclusions
In this, the first randomized comparative effectiveness trial
directly evaluating the use of a nicardipine infusion to
bolus labetalol in the ED management of acute hyperten-
sion, we demonstrated that patients receiving nicardipine
are more likely to have their BP controlled (OR 2.73, 95%
CI 1.1 to 6.7), defined as within the physician’s prospec-
tively defined target range, than patients treated with labe-
talol. Although this may be the result of administration
differences, this reflects actual clinical practice in how
these medications are utilized. Furthermore, the need for
rescue medications, or excessive BP lowering, did not
appear to differ between the two cohorts. Future investiga-
tion is needed to place our findings within the context of
hospital costs and resource allotment.
Key messages
￿ Hypertensive emergencies require immediate, con-
trolled BP reduction to avoid or limit end-organ
damage.
￿ In sufficient doses, both labetalol and nicardipine
lower BP.
￿ Patients treated with nicardipine were 2.7 times
more likely to be in the target range within 30 min-
utes, than those treated with labetalol.
￿ Overshoot of BP below the specified range
occurred in less than 15% of patients treated with
either nicardipine or labetalol.
￿ Although bradycardia was more common in the
labetalol group, no patient had a heart rate below 70
beats per minute.
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